Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors
Papulopustular rash (PPR) is the most frequent cutaneous adverse event during treatment with epidermal growth factor receptor inhibitors (EGFRis). Although often mild in severity, it can impair patients' quality of life and may also be a reason for discontinuing or changing the dose of the anti...
Saved in:
Main Authors: | Eleonora De Luca (Author), Pietro Sollena (Author), Lucia Di Nardo (Author), Ettore D'Argento (Author), Emanuele Vita (Author), Giampaolo Tortora (Author), Ketty Peris (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature
by: Pietro Sollena, et al.
Published: (2019) -
Papulopustular Facial Eruption in a Child: A Quiz
by: Louise Parke, et al.
Published: (2019) -
"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
by: Pietro Sollena, et al.
Published: (2022) -
Papulopustular eruptions of bilateral soles with facial erythematous papuloplaques in a 44-year-old female
by: Chih-Hsiang Chang, et al.
Published: (2010) -
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
by: Carmine Carbone, et al.
Published: (2019)